Formerly unanticipated long-term responses in advanced stages of NSCLC have been done, with 5- to 12-month OS of 20%–40% in unselected versus patients expressing high PD-L1 levels (67). This evidence concerns the gene CD274 and non-small cell lung carcinoma.